- | Clover Biopharma
In the pipeline: What the next wave of COVID-19 vaccines could look like
We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials – and how they could offer a point of difference to authorized vaccines.
- | Acepodia
Acepodia’s Approach To ACC & CAR Manufacturing Scalability
Acepodia CEO, President, & Co-founder Dr. Sony Hsiao and Dr. Mark Gilbert, VP of R&D, join Erin Harris and Matt Pillar for a discussion on the company’s approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates.
- | Cue Biopharma
Rogue antibodies could be driving severe COVID-19
Finding a rock-solid connection can be tough, because it’s difficult to show whether the infections are the cause of autoimmune disorders or whether they crop up in the body for another reason, says Anish Suri, president of Cue Biopharma, a company in Cambridge, Massachusetts, that is researching therapies to counter autoimmunity.
- | Clene Nanomedicine
Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease
Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases.
- | Immuneering
Disease-cancelling drugs: Immuneering raises $62m in Series B round
Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be used to support the company’s portfolio – particularly its lead candidate – as well as its computational biology services business.
- | Aridis Pharmaceuticals
JPM: Aridis CEO Truong on why the pandemic hasn’t bolstered antibiotics R&D and what needs to change
With its pipeline of bacteria-fighting monoclonal antibodies, Aridis is working to tackle the first two problems: injecting innovation into the space and testing its programs in a way that show they’re better than the incumbents rather than simply not worse.
- | DURECT
Here’s What 4 Biopharma CFOs Think About The Future Of Remote Work
Office interactions are definitely an important way to foster relationships between coworkers, establish and maintain a corporate culture, and foster creative thinking. This is particularly relevant when a company onboards new employees. However, new technologies, such as the wide-spread use of high-quality video meeting platforms, have enabled us to replace the in-person interactions to some extent and have made most of us more efficient and organized at times. While I don’t envision a future business organization that lacks an office environment entirely, I believe now that everyone has been forced to learn how to get things done in a virtual environment, and that biotechs will adopt a hybrid model of in-person and virtual interactions.
- | Anima Biotech
Biopharma Executive Perspectives on 2021
“The biggest thing that is really happening in the biotech industry…there is a new rich source of drugs. There is a goldmine, called mRNA, that some diggers have been digging for 30 years, finding a very small part of it,” said Yochi Slonim, co-founder and Chief Executive Officer of Anima Biotech, which is advancing ‘Translation Control Therapeutics,’ the first and only platform for the discovery of small molecule drugs that control mRNA translation.
